A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, ...
cost and safety benefits of an off-the-shelf antibody-based therapeutic. “Hinge’s GEM-DIMER technology has broad applicability across therapeutic areas and constructs, and we believe HB2198 ...
Conversely, 42% of patients with a high D-dimer level (>2.0 µg/ml) subsequently experienced a clinically relevant clotting event, in some cases in the absence of antiphospholipid antibodies or ...
The GEM-DIMER™ technology platform enables the creation of multivalent, multispecific antibody-based therapeutics that are designed to bind their targets cooperatively allowing for dramatically ...
A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell.
A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, ...
X-dimer. The researchers found that when the anti-cancer antibody binds to P-cadherin, it locks it into the X-dimer form. The stable X-form then triggers a chemical signal that causes that patch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback